| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
ZT 52656A hydrochloride selectively targets the kappa opioid receptor (KOR) as an agonist. The kappa opioid receptor is a G protein-coupled receptor that is activated by endogenous dynorphin peptides and mediates analgesic, anti-inflammatory, and aversive effects. Activation of KOR leads to inhibition of adenylyl cyclase, decreased cAMP levels, and modulation of ion channels, resulting in reduced neuronal excitability and pain transmission. ZT 52656A exhibits good receptor selectivity for KOR over other opioid receptor subtypes (mu and delta), which may contribute to its favorable side-effect profile. The compound has potential peripheral action properties, making it suitable for topical ocular application.
|
|---|---|
| ln Vitro |
ZT 52656A is a selective kappa opioid agonist that is intended to prevent or treat eye discomfort [1].
In vitro, ZT 52656A hydrochloride acts as a selective kappa opioid receptor agonist. The compound shows high affinity and selectivity for KOR in receptor binding assays. Functional assays demonstrate that ZT 52656A activates KOR-mediated signaling pathways including G protein activation and inhibition of cAMP production. The compound exhibits potent agonist activity with minimal activity at mu and delta opioid receptors. The selective activation of KOR provides analgesia without the abuse potential and respiratory depression associated with mu opioid agonists. The compound's in vitro profile supports its development as a peripherally acting analgesic for ocular pain. |
| ln Vivo |
In vivo, ZT 52656A hydrochloride is used for the prevention or alleviation of pain in the eye. The compound is administered topically to the eye, where it activates kappa opioid receptors in ocular tissues to reduce pain. Kappa opioid receptor agonists have been shown to produce analgesia in various pain models without the side effects associated with mu opioid receptor activation. ZT 52656A's peripheral action and ocular administration route minimize systemic exposure and central nervous system side effects. The compound has been evaluated in preclinical models of ocular pain and has demonstrated efficacy in reducing pain responses.
|
| Enzyme Assay |
In vitro receptor binding assays for ZT 52656A hydrochloride are performed using membrane preparations from cells expressing recombinant human kappa, mu, or delta opioid receptors. Radiolabeled ligands (e.g., [3H]-U69,593 for KOR, [3H]-DAMGO for MOR, [3H]-DPDPE for DOR) are used. Membranes are incubated with varying concentrations of ZT 52656A in assay buffer at room temperature for 60-90 minutes. Bound and free radioligands are separated by rapid filtration through glass fiber filters. Filter-bound radioactivity is quantified by liquid scintillation counting. Ki values are calculated using the Cheng-Prusoff equation. Selectivity ratios are determined by comparing Ki values across receptor subtypes. Functional assays measure [3⁵S]GTPgammaS binding to assess G protein activation.
|
| Cell Assay |
In vitro cellular assays for ZT 52656A hydrochloride are performed using cells expressing recombinant kappa opioid receptors, such as CHO or HEK-293 cells. Cells are cultured in appropriate medium and seeded in 96-well plates. Cells are treated with serial dilutions of ZT 52656A (0.001-10 microM) for 15-30 minutes. Intracellular cAMP levels are measured using a competitive ELISA or HTRF-based detection kit following forskolin stimulation. Agonist activity is determined by the compound's ability to inhibit forskolin-stimulated cAMP accumulation. EC₅0 values are calculated from dose-response curves using nonlinear regression. Potency, efficacy, and selectivity are characterized.
|
| Animal Protocol |
In vivo animal studies for ZT 52656A hydrochloride are conducted in models of ocular pain. In typical protocols, rabbits or mice are used to evaluate corneal pain or inflammation-induced hyperalgesia. Corneal pain models involve application of hypertonic saline or chemical irritants to the cornea, and pain responses (blinking, wiping) are quantified. ZT 52656A is administered topically as eye drops at concentrations of 0.1-1% (w/v) before or after pain induction. Pain scores are recorded at various time points. Ocular tolerability is assessed by slit-lamp examination for corneal opacity, conjunctival redness, and other signs of irritation. Systemic exposure is measured by collecting blood samples and analyzing drug concentrations by LC-MS/MS.
|
| ADME/Pharmacokinetics |
ZT 52656A hydrochloride (CAS#: 115730-24-0) has molecular formula C1₉H24ClN3O and molecular weight 345.87. The compound is a synthetic small molecule that acts as a selective kappa opioid receptor agonist. It is used for the prevention or alleviation of pain in the eye. The hydrochloride salt form enhances aqueous solubility for topical ophthalmic formulations. The compound is a research chemical for laboratory use only, not for human therapeutic applications without appropriate authorization. Storage should be at -20degC, protected from light and moisture.
|
| Toxicity/Toxicokinetics |
Toxicological information for ZT 52656A hydrochloride is limited as the compound is a research chemical. Based on its mechanism as a kappa opioid receptor agonist, potential adverse effects may include dysphoria, sedation, and diuresis at systemic doses. However, topical ocular administration minimizes systemic exposure. Ocular tolerability studies have evaluated the compound for signs of irritation or toxicity in the eye. The compound should be handled with standard laboratory precautions including the use of personal protective equipment and working in a well-ventilated area. Avoid inhalation, ingestion, and skin contact.
|
| References | |
| Additional Infomation |
ZT 52656A hydrochloride (CAS#: 115730-24-0) is a selective kappa opioid receptor (KOR) agonist being developed for the treatment of ocular pain. KOR agonists provide analgesia without the abuse potential, tolerance, and respiratory depression associated with mu opioid receptor agonists, making them attractive for pain management applications. ZT 52656A is administered topically to the eye for the prevention or alleviation of ocular pain. The compound is a research chemical and is not approved for clinical use. As of the current date, ZT 52656A hydrochloride remains an investigational compound for ophthalmic pain indications.
|
| Molecular Formula |
C19H26CLF3N2O
|
|---|---|
| Molecular Weight |
390.870754718781
|
| Exact Mass |
390.168
|
| CAS # |
115730-24-0
|
| PubChem CID |
14810961
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
26
|
| Complexity |
440
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(CC1=CC=C(C=C1)C(F)(F)F)N2CCCCC2CN3CCCC3.Cl
|
| InChi Key |
RPYYEZAVUKVVFN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H25F3N2O.ClH/c20-19(21,22)16-8-6-15(7-9-16)13-18(25)24-12-2-1-5-17(24)14-23-10-3-4-11-23;/h6-9,17H,1-5,10-14H2;1H
|
| Chemical Name |
1-[2-(pyrrolidin-1-ylmethyl)piperidin-1-yl]-2-[4-(trifluoromethyl)phenyl]ethanone;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~35.71 mg/mL (~91.36 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.32 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (5.32 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (5.32 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5584 mL | 12.7920 mL | 25.5840 mL | |
| 5 mM | 0.5117 mL | 2.5584 mL | 5.1168 mL | |
| 10 mM | 0.2558 mL | 1.2792 mL | 2.5584 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
